[REVISION HISTORY]

Evonik corporate expansion and strategic growth

1 recorded revision of this situation.

What changed

2026-11-03 20:17 UTC → 2026-11-05 08:32 UTC · added ~~removed~~

Evonik has initiated a multi-faceted growth strategy focused on sustainability and pharmaceutical manufacturing. The company aims to generate €1.5 billion in additional revenue by 2032 through innovations in biotechnology, the energy transition, and the circular economy. This includes developing renewable biosurfactants and carbon capture technologies. In the pharmaceutical sector, Evonik is investing over CAD 150 million to expand operations in Vancouver, Canada, to produce lipid-based drug delivery systems, such as lipid nanoparticles used in mRNA vaccines. This is complemented by a new lipid manufacturing site in Lafayette, Indiana. Furthering its industrial capacity, the company has invested €52 million to expand its silicone platform at the Essen Goldschmidtstrasse site in Germany. This expansion involves constructing a new production plant and tank farm to increase capacity for organomodified silicones used in automotive, insulation, and personal care sectors. The project included expanding the site area from 32 to 35 hectares and installing a 150-meter pipe bridge to connect four production units and 15 manufacturing assets. According to company officials, the investment is intended to strengthen supply chain resilience, optimize logistics, and reduce the need to transport intermediates between sites. During its Q3 2026 earnings call, the company also introduced a new executive board setup under Interim CEO Claus ~~Rettig.~~ Rettig, who previously led the Asia region.

Versions

Select a version to see what changed compared to the one before it.